Revvity (RVTY)
Health Care · Life Sciences Tools & Services · NYSE
Revvity is a global life sciences company that provides the essential tools and services for researchers to accelerate drug discovery and clinicians to deliver more precise diagnostics.
What Revvity does
Revvity is a life sciences and diagnostics company that provides technologies, specialized solutions, and services for drug discovery, research, and clinical diagnostics. Its portfolio spans a broad range of scientific instrumentation, reagents, informatics, and laboratory services intended to improve human health outcomes.
Themes: drug discovery & development, clinical diagnostics, life science research tools, laboratory automation
Fundamentals
- Price$124.75 as of 2026-08-21 close
- Market cap$13.9B as of 2026-08-21
- 1-year return+39.1% 2025-08-21 close $89.67 → 2026-08-21 close $124.75
- P/E55.10 as of 2026-08-24
- Net margin+8.2% as of 2026-08-24
- Gross margin+55.0% as of 2026-08-24
- ROE+3.3% as of 2026-08-24
- Debt / equity0.44 as of 2026-08-24
- Revenue growth (YoY)+4.0% as of 2026-08-24
- Revenue CAGR (3y)-9.3% SEC XBRL
- Beta1.09 as of 2026-08-24
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +0.3%; at least 3 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How RVTY compares in its sector
- price-to-earnings ratiotop 25% 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 25% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- indicated dividend yieldbottom 25% 71 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
RVTY is not currently in any published Top 10 list. Its scores are below.
Long-term score
42.5 #752 of 987 scored · #44 of 57 in Health Care
Long-term trend 74th (it is at or near its highest point of the past year) and financial health 70th (free cash flow margin 19.2%, debt to equity 0.4); weakest is growth (18th, 3-year revenue CAGR -9.3%, revenue growth year over year 4.1%).
Short-term score
49.2 #844 of 1,704 scored · #147 of 240 in Health Care
Volume and participation 94th: trading volume is about normal versus its 30-day average; trend 71st: the price is 6% above the average price paid over the period covered, so the typical buyer over that stretch is showing a gain; weakest is catalysts 33rd: open-market insider buys in 90 days 0, analysts' average price target is unchanged from the prior reading. Its score is docked 10 points for overextended (RSI above 75 or stochastic above 90).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, RVTY's dividend was covered by reported results (earnings payout 14%, free-cash-flow payout 6%). This describes past coverage, not a forecast.
- Earnings payout14% dividends / net income
- Free-cash-flow payout6% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How Revvity looks technically
Revvity (RVTY) is trading 24.1% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 41 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 69, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive). It just made a new 20-day high, pushing above its recent trading range. It is trading right at its highest price of the past year (its 52-week high).
Trend
8
| Distance from the 200-day | it is trading 24.1% above its 200-day average, the long-term trend line — a longer-term uptrend | +24.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $111.17 | $111.17 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $100.50 | $100.50 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 17 calendar days ago — the swings before that are what the structure reading is measured on | 17 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 107.73. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 41 trading days ago — a "golden cross", a bullish long-term signal | 41 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend | 14.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 69, neither overbought (above 70) nor oversold (below 30) | 68.6 |
|---|---|---|
| Position in its 14-day range | it is trading right at the top of its 14-day range ($107.73 to $124.97) — its "stochastic" reading is 99 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 98.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive) | 3 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $124.97 | $124.97 |
|---|---|---|
| From the 52-week high | it is trading right at its highest price of the past year (its 52-week high) | -0.2% |
| Above the 52-week low | it is 53.6% above its 52-week low (its lowest price of the past year) | +53.6% |
| Below the 52-week high | it is at or near its highest point of the past year | 0.2% |
| Since a 20-day breakout | it just made a new 20-day high, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $203.16 (set on 2021-12-31) | $203.16 |
| Given back of the 52-week move | over the past year its closes ranged ($82.26 to $124.75), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $97.13 to $98.49. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 38.6% below its all-time high | -38.6% |
| Nearest price level | it is trading 2.3% below a resistance level at $127.57 — a price it turned at four times since 2024-09-19, most recently on 2025-01-30. Since 2024-08-21 it has 12 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +2.3% |
| All-time low | its lowest closing price on record is $0.4375 (set on 1974-09-12) | $0.4375 |
| Above the all-time low | it is 28414.3% above its all-time low | +28,414% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 42nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $3.97 between its high and its low — about 3.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $3.97 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $107.86 and $123.32 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $107.86 – $115.59 – $123.32 |
| Typical daily range (% of price) | its price moves about 3.2% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.2% |
| Stretch from the 200-day average | it is trading 6.1 daily ranges above its 200-day average price (24.1% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.59× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a bullish engulfing | 7 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 7 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.3% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.3% |
|---|---|---|
| Gap filled | a 2.4% gap up opened on 2026-07-23 has been "filled" 20 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 20 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +9.67% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 10.5 percentage points (the stock gained 12.9% while the market gained 2.3%) | +10.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 27.7 percentage points (the stock gained 30.8% while the market gained 3.1%) | +27.7% |
| vs market, 6 months | over the past 6 months this stock beat the market by 13.3 percentage points (the stock gained 24.3% while the market gained 11.1%) | +13.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 18.6 percentage points (the stock gained 39.1% while the market gained 20.5%) | +18.6% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 15% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 8.1% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +14.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 21% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $103.08 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +21.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 6% above the average price paid since it last reported on 2026-08-04 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $117.46 — a volume-weighted average of daily closes over 14 sessions, not a true tick-by-tick VWAP. | +6.2% |
Price levels it has turned at before
RVTY last closed at $124.75 on 2026-08-21. Since 2024-08-21 it has turned at 12 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $127.57 | Resistance | 2.3% above the last close | turned there four times · 2024-09-19 to 2025-01-30 |
| $120.93 | Support | 3.1% below the last close | turned there three times · 2024-09-25 to 2025-03-10 |
| $116.10 | Support | 6.9% below the last close | turned there six times · 2024-09-06 to 2026-08-04 |
| $109.58 | Support | 12.2% below the last close | turned there twice · 2024-12-30 to 2025-02-12 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $107.73.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $122.73 and $132.00 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $107.73.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Near the 52-week high · Broke out to a new 20-day high · MACD just crossed bullish (12/26/9) · trendless / choppy (low ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$121.07 range $100.00 – $145.00; median $122.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for RVTY
- Consensus EPS estimate$1.29 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on research and development spending by pharmaceutical, biotechnology, and academic customers.","Risks associated with integrating acquired businesses and realizing anticipated synergies.","Potential disruption to global supply chains and manufacturing operations."]
What changed in the latest 10-Q
AI-assisted comparison of RVTY's 10-Q filed 2026-05-12 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Added fiscal year calendar information: fiscal year 2026 includes 53 weeks; fiscal year 2025 included 52 weeks (filed 2026-05-12)
- Added detail that Q1 FY2026 revenue increase included 3% from favorable foreign exchange and 1% from acquisitions (filed 2026-05-12)
- Added specific tariff impact disclosure: tariffs increased cost of revenue by approximately $8 million in Q1 FY2026, with net gross margin impact of approximately $6 million after mitigation efforts (filed 2026-05-12)
- Added reference to February 20, 2026 U.S. Supreme Court ruling on International Emergency Economic Powers (filed 2026-05-12)
- Removed:
- Removed Operating Model Changes disclosure that was in older filing regarding Applied Genomics integration and segment restructuring effective fiscal year 2025 (filed 2025-11-04)
- Removed Q3 FY2025 period-over-period discussion and related revenue/margin comparisons to Q3 FY2024 (filed 2025-11-04)
- Removed nine-month revenue discussion and comparisons for nine months ended September 28, 2025 vs. September 29, 2024 (filed 2025-11-04)
- Removed reference to Form 10-K for fiscal year ended December 29, 2024; replaced with reference to Form 10-K for fiscal year ended December 28, 2025 (filed 2025-11-04 vs. filed 2026-05-12)
- Reworded:
- Changed reference period from 'nine months ended September 28, 2025' to 'three months ended April 5, 2026' for current period analysis
- Changed comparison period from 'three months ended September 29, 2024' to 'three months ended March 30, 2025'
- Changed Cost of Revenue discussion to reflect Q1 FY2026 period ($323.5 million) instead of Q3 FY2025 period ($324.3 million)
- Notes:
- Newer filing text appears truncated at end of Cost of Revenue section and does not include complete tariff discussion or subsequent sections
- Older filing text also appears truncated at end of Cost of Revenue section
- Comparison is between Q1 FY2026 (3-month period ended April 5, 2026) and Q3 FY2025 (3-month period ended September 28, 2025), representing different fiscal quarters in different fiscal years
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days.
- Last 90 days0 buys · 1 sell ($9306) — 1 selling insider
- Last 180 days0 buys · 2 sells ($16730) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-20. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about RVTY's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 12 matched disclosures for RVTY from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding RVTY as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 12,165,796
- Reported value $1,065,845,476
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
RVTY had 7,052,617 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
RVTY had 6.32% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.64 days to cover at the same settlement.
- Reported short interest (shares) 7,052,617
- Short interest (% of shares outstanding) 6.32%
- Prior settlement (shares) 7,434,687
- Reported change -5.14%
- Days to cover (reported) 4.64
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Thermo Fisher Scientific (TMO)
- Danaher (DHR)
- Agilent Technologies (A)
- Waters (WAT)
- Bio-Rad Laboratories (BIO)
- Bruker (BRKR)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare RVTY vs…
Revvity is found in…
Frequently asked questions
What does Revvity (RVTY) do?
Revvity is a life sciences and diagnostics company that provides technologies, specialized solutions, and services for drug discovery, research, and clinical diagnostics. Its portfolio spans a broad range of scientific instrumentation, reagents, informatics, and laboratory services intended to improve human health outcomes.
What sector is Revvity (RVTY) in?
Revvity (RVTY) is classified in the Health Care sector. Its industry is Life Sciences Tools & Services. It trades on NYSE.
Does RVTY pay a dividend?
Yes — Revvity (RVTY) pays a dividend, with an indicated yield of about 0.31% and at least 3 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-08-24). Informational only — not financial advice.
Who are Revvity's (RVTY) competitors?
Notable peers of Revvity (RVTY) include Thermo Fisher Scientific, Danaher, Agilent Technologies, Waters and Bio-Rad Laboratories. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in RVTY?
Yes — we hold 12 matched STOCK Act disclosures for RVTY from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Revvity (RVTY) overbought or oversold right now?
Revvity (RVTY) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 69, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on RVTY come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.